Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
crispr
editas medicine
3
×
life sciences
national blog main
allergan
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
fda
gene editing
ipo
katrine bosley
nasdaq
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
advaxis
aimmune therapeutics
akouos
alder biopharmaceuticals
alexander hardy
What
ceo
3
×
bio
crispr
editas
katrine
medicine
roundup
acquisitions
allergan
announced
big
blessing
bosley
bosley's
bosley’s
bridge
bucks
cas
check
clinical
collabs
covid
crime
cusp
daniel
deal
depart
departure
editing
exit
experimental
gene
gilead
gilead’s
guiding
help
humans
introduce
ipo
medicines
Language
unset
Current search:
biotech
×
ceo
×
" editas medicine "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial